Tags

Type your tag names separated by a space and hit enter

Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin immunotherapy.
Can J Urol. 2009 Apr; 16(2):4589-91.CJ

Abstract

Intravesical Bacillus Calmette-Guérin (BCG) is widely used as an adjuvant therapy in the treatment of superficial bladder cancer. BCG is administered as a live, attenuated form of Mycobacterium bovis, and acts as an immunomodulary agent to delay tumor progression. BCG is generally well tolerated, though localized and systemic infectious complications may occur. A literature search revealed that tuberculous epididymitis is a rarely reported complication of intravesical BCG therapy. We report the case of an 82-year-old male who developed tuberculous epididymitis while undergoing intravesical BCG treatment for transitional cell carcinoma of the bladder. Right orchiectomy was performed, followed by rifampin and isoniazid therapy once M. bovis was identified as the infectious agent. The patient responded well to these treatments, and made a full recovery. Tuberculous epididymitis is an uncommon complication resulting from intravesical BCG therapy, which is likely explained by retrograde migration from the prostatic urethra in this case.

Authors+Show Affiliations

Department of Urologic Sciences, University of British Columbia (Island Medical Program), Victoria, BC, Canada.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

19364433

Citation

Hoag, Nathan, et al. "Tuberculous Epididymitis Following Intravesical Bacillus Calmette-Guérin Immunotherapy." The Canadian Journal of Urology, vol. 16, no. 2, 2009, pp. 4589-91.
Hoag N, Pommerville PJ, Kibsey PC, et al. Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin immunotherapy. Can J Urol. 2009;16(2):4589-91.
Hoag, N., Pommerville, P. J., Kibsey, P. C., Cavers, D. J., & Eddy, R. J. (2009). Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin immunotherapy. The Canadian Journal of Urology, 16(2), 4589-91.
Hoag N, et al. Tuberculous Epididymitis Following Intravesical Bacillus Calmette-Guérin Immunotherapy. Can J Urol. 2009;16(2):4589-91. PubMed PMID: 19364433.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tuberculous epididymitis following intravesical Bacillus Calmette-Guérin immunotherapy. AU - Hoag,Nathan, AU - Pommerville,Peter J, AU - Kibsey,Pamela C, AU - Cavers,Douglas J, AU - Eddy,Richard J, PY - 2009/4/15/entrez PY - 2009/4/15/pubmed PY - 2009/5/20/medline SP - 4589 EP - 91 JF - The Canadian journal of urology JO - Can J Urol VL - 16 IS - 2 N2 - Intravesical Bacillus Calmette-Guérin (BCG) is widely used as an adjuvant therapy in the treatment of superficial bladder cancer. BCG is administered as a live, attenuated form of Mycobacterium bovis, and acts as an immunomodulary agent to delay tumor progression. BCG is generally well tolerated, though localized and systemic infectious complications may occur. A literature search revealed that tuberculous epididymitis is a rarely reported complication of intravesical BCG therapy. We report the case of an 82-year-old male who developed tuberculous epididymitis while undergoing intravesical BCG treatment for transitional cell carcinoma of the bladder. Right orchiectomy was performed, followed by rifampin and isoniazid therapy once M. bovis was identified as the infectious agent. The patient responded well to these treatments, and made a full recovery. Tuberculous epididymitis is an uncommon complication resulting from intravesical BCG therapy, which is likely explained by retrograde migration from the prostatic urethra in this case. SN - 1195-9479 UR - https://www.unboundmedicine.com/medline/citation/19364433/Tuberculous_epididymitis_following_intravesical_Bacillus_Calmette_Guérin_immunotherapy_ L2 - http://www.canjurol.com/abstract.php?ArticleID=&version=1.0&PMID=19364433 DB - PRIME DP - Unbound Medicine ER -